Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH)

Authors

DOI:

https://doi.org/10.33448/rsd-v10i10.18921

Keywords:

Non-alcoholic Fatty Liver Disease; Drug Therapy; Liraglutide.

Abstract

To evaluate the effects of liraglutide administration on NASH. Consists of a systematic review of the literature in the main virtual libraries: US National Library of Medicine National Institutes of Health (PubMed), Biblioteca Virtual de Saúde (BVS), Scientific Electronic Library Online (SCIELO) and Latin American and Caribbean Literature in Health Sciences (LILACS) in the last five years, admitting articles from clinical trials. Liraglutide is an analogue of the glacagon 1-like peptide hormone (GLP-1) that acts in suppressing appetite and de novo lipogenesis (DNL), decreasing glucagon release, increasing insulin release and sensitization, among others. For these reasons, its fronts to combat NASH range from the reduction and control of the lipid profile, to the repair of hepatocytes. Currently, with the obesogenic environment found in society, drug therapy has become a great ally of the medical community, as well as in facilitating goals for the patient. The use of liraglutide in NASH proved to be effective in slowing and resolving it, with therapies ranging from 26 to 48 weeks and doses ranging from 0,9 mg to 3,0 mg.

References

Araújo, A. R. et al. (2018). Global epidemiology of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: What we need in the future. Liver International, 38, 47-51.

Armstrong, M. J. et al. (2016). Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of hepatology, 64(2), 399-408.

Armstrong, M. J. et al. (2016). Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet, 387(10019), 679-690.

Arrese, M., Cabrera, D., & Barrera, F. (2015). Obeticholic acid: expanding the therapeutic landscape of NASH. Annals of hepatology, 14(3), 430-432.

Bouchi, R. et al (2016). Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocrine journal, EJ16-0449.

Britton, L. J., Subramaniam, V. N., & Crawford, D. H. (2016). Iron and non-alcoholic fatty liver disease. World journal of gastroenterology, 22(36), 8112.

Caldwell, S. (2016). NASH Therapy: Omega 3, Vitamin E, Insulin Sensitizers and Statins. In Single Topic Symposium (STS) (Vol. 2016, No. 2, pp. 25-26).

European Association for the Study of The Liver, & European Association for the Study of Diabetes (EASD. (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obesity facts, 9(2), 65-90.

Estes, C. et al. (2018). Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 67(1), 123-133.

European Association for Study of Liver. (2015). EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of hepatology, 63(1), 237-264.

Feng, W. et al. (2017). Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease. Journal of diabetes, 9(8), 800-809.

Feng, W. et al. (2019). Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non‐alcoholic fatty liver disease: a randomized trial. Journal of diabetes investigation, 10(2), 399-407.

Gawrieh, S., & Chalasani, N. (2018). Emerging treatments for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clinics in liver disease, 22(1), 189-199.

Khoo, J. et al. (2017). Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non‐alcoholic fatty liver disease: a pilot randomized trial. Diabetes, Obesity and Metabolism, 19(12), 1814-1817.

Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015). Gut–liver axis, nutrition, and non-alcoholic fatty liver disease. Clinical biochemistry, 48(13-14), 923-930.

Lainé, F. et al. (2017). Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients. Hepatology, 65(2), 465-474.

Lassailly, G. et al. (2015). Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology, 149(2), 379-388.

Lebeaupin, C. et al. (2018). Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. Journal of hepatology, 69(4), 927-947.

Lonardo, A. et al. (2015). Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease, 47(12), 997-1006.

Matikainen, N. et al. (2019). Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single‐centre randomized controlled study. Diabetes, obesity and metabolism, 21(1), 84-94.

Monaco-Ferreira, D. V., & Leandro-Merhi, V. A. (2017). Weight regain 10 years after Roux-en-Y gastric bypass. Obesity surgery, 27(5), 1137-1144.

Neuschwander-Tetri, B. A. et al. (2015). Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet, 385(9972), 956-965.

Petit, J. M. et al. (2017). Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the Lira-NAFLD study. The Journal of Clinical Endocrinology & Metabolism, 102(2), 407-415.

Rametta, R. et al. (2016). Hepcidin resistance in dysmetabolic iron overload. Liver International, 36(10), 1540-1548.

Rinella, M. E. (2015). Nonalcoholic fatty liver disease: a systematic review. Jama, 313(22), 2263-2273.

Rotman, Y., & Sanyal, A. J. (2017). Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut, 66(1), 180-190.

Singh, S. et al. (2015). Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clinical gastroenterology and hepatology, 13(4), 643-654.

Smits, M. M. et al. (2016). Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia, 59(12), 2588-2593.

Stål, P. (2015). Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance. World Journal of Gastroenterology: WJG, 21(39), 11077.

Tuzzo, S. A., & Braga C. F. (2016). O processo de triangulação da pesquisa qualitativa: o metafenômeno como gênese. Revista Pesquisa Qualitativa, São Paulo, SP, v.4, n.5, p. 140-158.

Van Herck, M. A., Vonghia, L., & Francque, S. M. (2017). Animal models of nonalcoholic fatty liver disease—a starter’s guide. Nutrients, 9(10), 1072.

Vilar-Gomez, E. et al.(2015). Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 149(2), 367-378.

Wang, M., & Kaufman, R. J. (2016). Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature, 529(7586), 326-335.

Willy, J. A. et al. (2015). CHOP links endoplasmic reticulum stress to NF-κB activation in the pathogenesis of nonalcoholic steatohepatitis. Molecular biology of the cell, 26(12), 2190-2204.

Wong, R. J. et al. (2015). Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology, 148(3), 547-555.

Yan, J. et al. (2019). Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology, 69(6), 2414-2426.

Younossi, Z. M. et al. (2016). Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84.

Zelber-Sagi, S., Godos, J., & Salomone, F. (2016). Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therapeutic advances in gastroenterology, 9(3), 392-407.

Published

14/08/2021

How to Cite

PINTO, A. C. F. L. V. .; MEDEIROS FILHO, O. B. de; SOUSA, M. N. A. de; LINS, H. D. M. N. . Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH). Research, Society and Development, [S. l.], v. 10, n. 10, p. e389101018921, 2021. DOI: 10.33448/rsd-v10i10.18921. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/18921. Acesso em: 25 oct. 2021.

Issue

Section

Health Sciences